A review of clinical trials with fluoroquinolones with an emphasis on new agents

10.1055/s-0028-1129486

10.1128/AAC.17.2.103

10.1056/NEJM199611073351907

10.1002/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W

10.1517/13543784.7.5.761

10.1093/clinids/18.1.1

10.1016/S0140-6736(67)92346-X

10.1016/S0140-6736(77)92892-6

10.1056/NEJM197810052991402

10.1016/S0140-6736(63)92350-X

10.1136/bmj.1.5385.728

10.1056/NEJM196704132761508

10.1097/00006454-198912000-00019

10.1016/S0732-8893(96)00135-6

SIMOR AE, 1996, Antimicrob. Agents Chemother., 40, 2190, 10.1128/AAC.40.9.2190

10.1016/S0149-2918(00)88266-1

10.1093/jac/40.5.639

10.1093/jac/41.1.103

10.1016/S0732-8893(98)00072-8

DONG Y, 1999, Antimicrob. Agents Chemother., 43, 1756, 10.1128/AAC.43.7.1756

10.1093/jac/38.6.1023

10.1128/AAC.39.12.2635

10.1128/AAC.39.2.513

JOHNSON JH, 1992, R andREWS JM et al.: Pharmacoki-netics and inflammatory fluid penetration of sparfloxacin. Antimicrob. Agents Chemother., 36, 2444

PIDDOCK LJV, JOHNSON M, RICCI V et al., 1998, Antimicrob. Agents Chemother., 42, 2956, 10.1128/AAC.42.11.2956

YAMAMOTO T, 1996, Antimicrob. Agents Chemother., 40, 2756, 10.1128/AAC.40.12.2756

10.1086/513953

10.1093/clinids/18.4.501

10.1001/jama.1996.03530260048030

10.1016/S0002-9343(96)00255-0

10.1128/AAC.38.10.2419

10.1086/514953

10.1056/NEJM199508243330803

BERRY V, 1998, Antimi-crob. Agents Chemother., 42, 3193, 10.1128/AAC.42.12.3193

10.1016/S0732-8893(96)00162-9

10.1093/jac/40.6.797

10.1517/13543784.8.2.123

EDNIE LM, 1998, Antimicrob. Agents Chemother., 42, 2459, 10.1128/AAC.42.9.2459

10.1093/jac/34.6.875

ERNST ME, 1997, J. Health-Syst Pharm., 54, 1997

10.1007/BF01691581

FILE TM JR, SEGRETI J, DUNBAR L et al., 1997, and/or oral levofloxacin versus ceftriaxone and/orcefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother., 41, 1965

FOGARTY C, 1999, Infect. Med., 16

ELLER J, 1998, Relation between bacteriologic etiology and lung function. Chest, 122, 1542

MIRAVITLLES M, 1999, Study Group of Bacterial Infection in COPD. Chest, 116, 40

CELLI BR, 1995, Am. J. Respir. Crit. Care Med., 152, S77–S120

10.7326/0003-4819-106-2-196

10.1093/jac/44.4.501

10.1097/00063198-199605000-00004

HATTAN J, 1994, Ann. Pharmacother., 28, 1264, 10.1177/106002809402801110

10.1016/S0732-8893(98)00112-6

10.7326/0003-4819-111-11-906

BUMP RC, 1990, Current role of single-dose therapy. J. Reproduc. Med., 35, 785

10.1016/S0090-4295(98)00160-5

10.1001/archfami.3.2.157

LANGTRY HD, 1998, Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs, 56, 487

ITO H, 1994, Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother., 38, 2014

10.1016/S1369-5274(99)00008-9

10.1073/pnas.94.25.13991

ZHAO X WANG J-Y, 1998, Antimicrob. Agents Chemother., 42, 956, 10.1128/AAC.42.4.956

10.1093/jac/36.2.431

10.1016/S0732-8893(98)00083-2

DEGUCHI T, 1997, Antimi-crob. Agents Chemother., 41, 1609, 10.1128/AAC.41.7.1609

10.2165/00002018-199921050-00005

JOHNSON RH, 1996, Infect. Dis. Gun. Prac., 5, 265

10.1016/S0149-2918(97)80050-1

10.2165/00044011-199917010-00003

10.1093/jac/42.1.114

O'DOHERTY B, 1998, Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group. Eur. j Clin. Microbic)]. Infect. Dis., 17, 441

HEYSTEK MJ, TELLARINI M, SCHMITZ H, KRASEMANN C, THE PID STUDY GROUP: Efficacy and safety of moxifloxacin (MFX) vs. ciprofloxacin plus doxycy-cline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). 21st International Congress of Chemotherapy Birmingham, UK, (July 1999).

HOEFFKEN G, MEYER HP, WINTER J, VERHOEF L, THE CAP 1 STUDY GROUP: Efficacy and safety of moxifloxa-cin (MFX) vs. clarithromcyin (CLR) for the treatment of community-acquired pneumonia (CAP). 21st International Congress of Chemotherapy Birmingham, UK, (July 1999).

10.1016/S0149-2918(99)80046-0

PFAU A, 1993, J. Urol., 149, 532, 10.1016/S0022-5347(17)36137-2

IRAVANI A, 1995, The minimum effective dose. The Urinary Tract Infection Study Group. Arch. Intern. Med., 155, 485